PRIME-CKD

?? PRIME-CKD consortium leader hiddo lambers heerspink delivered an inspiring presentation at the 7th Annual CKD Drug Development Summit in Boston. He highlighted the significant variations in both risk and response to guideline therapies for chronic kidney disease (CKD). During his talk, he emphasized the substantial differences in underlying mechanisms across various CKD stages and etiologies. While biomarker-guided treatment offers a promising solution, a considerable gap remains between successful biomarker discovery and clinical implementation. PRIME-CKD aims to bridge this gap by integrating discovery, validation, and clinical application. ?? Learn more by viewing Hiddo’s presentation here https://lnkd.in/efKhMqxp ?? Stay updated on PRIME-CKD, visit our?website: https://lnkd.in/eACWuMQJ

?? Today, on World Kidney Day, the PRIME-CKD consortium is committed to raising awareness of the vital role kidneys play in our overall health and to reducing the prevalence and impact of kidney disease and related health issues worldwide. Through pioneering systems medicine research and succesful biomarker discovery, the PRIME-CKD consortium possesses the collective expertise to validate and implement pharmacodynamic biomarkers in clinical practice. This enables the personalization and optimization of pharmacotherapy for patients with CKD. In collaboration with a growing stakeholder network, we strive to advance more effective and personalized treatments for CKD patients. ?? To join our stakeholder network or stay updated on PRIME-CKD, visit our?website: https://lnkd.in/eACWuMQJ

?? The stakeholder network of the PRIME-CKD consortium plays a vital role in advancing biomarker research for chronic kidney disease (CKD). Over the past year, patient representatives, medical professionals, industrial partners, and regulatory organizations have collaborated closely to guide the strategic direction of the research. Their input has been instrumental in shaping both the overall approach and the practical execution of key research initiatives. ?? A primary objective of PRIME-CKD is to develop a comprehensive roadmap for biomarker research, with a particular focus on CKD patients. To achieve this, the consortium has been proactively identifying opportunities and addressing bottlenecks in biomarker research before the clinical trials start by gathering insights from their stakeholders. Read the full article on www.prime-ckd.com to learn more about the proces: https://lnkd.in/e_g9NNiM Special thanks to Renske Grupstra, Carine B. and @Marte Opseth Rygg

? Reflecting on the highlights of ASN Kidney Week 2024 ? Various co-workers and partners of the PRIME-CKD consortium attended Kidney Week. They participated in poster presentations, lectures, receiving awards, or were simply attending as listeners. “There was an impressive focus on personalized/precision medicine, which greatly helped to spotlight the PRIME-CKD project,” noted Professor @Maria?F.?Gomez (Lund University Diabetes Centre), vice-coordinator of PRIME-CKD. Wenjun Ju (University of Michigan, leader WP2) and Erik Moedt (PhD, University Medical Center Groningen), presented study results during the “Diabetic Kidney Disease - Clinical: Novel Insights into Precision Medicine” session on Thursday, October 24. Project leader hiddo lambers heerspink generated significant (media) attention with the remarkable results from his SMART study on the effects of semaglutide in patients with chronic kidney disease. On Friday, October 25, Heerspink, who said to be “deeply honored to receive this award,” accepted the Donald W. Seldin Young Investigator Award for his contributions and groundbreaking work as a clinical scientist in nephrology. Watch his portrait and talk in this video https://lnkd.in/e8RWCSUi (starting at 27:00). Overall, a productive and encouraging Kidney Week for PRIME-CKD! ?? Read more on PRIME-CKD on the website: https://lnkd.in/eWg9-Kyv

?? PRIME-CKD at American Society of Nephrology Many of our consortium partners will be attending and participating in #KidneyWeek 2024 this week. There will be several poster presentations by PhD students from UMCG, along with oral presentations by our partners. Notably, hiddo lambers heerspink will be presenting two clinical trials. Additionally, don’t miss the award ceremony on Friday, October 25, where Hiddo Heerspink will be honored with?the Donald W. Seldin Young Investigator Award! ?? Please check the event calender on our website on where and when to find us: https://lnkd.in/eHyc8pqP #ckd #nephrology #kidney #asn

?? Publication BePRECISE in Nature Magazine An important?publication?in the field of precision medicine, to which?PRIME-CKD PI @Maria Gomez?from Lund University contributed, has been published in?Nature Medicine https://lnkd.in/gvj-Tg9M. The aim of this publication is to standardize the reporting of research findings in personalized medicine, thereby simplifying the comparison of data across different studies. Currently, there are no specific guidelines for reporting precision medicine research. The BePRECISE consortium (Better Precision-data Reporting of Evidence from Clinical Intervention Studies & Epidemiology) aims to address this gap. A key outcome of this publication is the BePRECISE?checklist (https://lnkd.in/ee8T8ddR), which serves as a valuable tool in this process. “There is a tremendous amount of precision medicine research that is underway, and some great examples where the research is impacting clinical practice. That research shows that precision medicine has the potential to be a practical and economically viable alternative to current practices for disease prevention, diagnosis, treatment, and prognosis. The reporting guidelines are timely and needed for efficient translation of precision medicine research into practice”, says @Maria F. Gomez, Professor of Physiology at LUDC and part of the guidelines committee.

(A little over) one year of PRIME-CKD. On our website we give an update on where we are standing after one year and what we already achieved: https://lnkd.in/ezh2Ayaq ?? Click to watch the aftermovie of our annual meeting last spring in Valencia to learn more about the consortium and our goals. ?? Follow our event page to stay informed on our whereabouts!

?? The PRIME-CKD consortium partner Renalytix and the Steno Diabetes Center Copenhagen announced a collaboration aimed at advancing precision medicine solutions for patients with Diabetes and Chronic Kidney Disease (DKD). A great step that aligns with the objectives of the PRIME-CKD project! Read the full article and press release on our website: https://lnkd.in/evtaMetw #ckd #diabetes #pckd #biotech